NCT06021977View on ClinicalTrials.gov

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Refractory/Relapsed Autoimmune Hemolytic Anemia
Interventions
DRUG

Zanubrutinib

Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.

Trial Locations (1)

300131

RECRUITING

Regenerative Medicine Center, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER